![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 5, 3793-3800, February 1, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of
Received for publication, August 6, 2001, and in revised form, November 1, 2001
Paneth cells in small intestinal crypts secrete
microbicidal Gene-encoded antimicrobial peptides are evolutionarily conserved
molecules that all known species elaborate as components of innate
immunity (1). Generally containing fewer than 40 amino acids, these
biochemically diverse peptides have secondary structures that range
from linear Paneth cells participate in innate mucosal immunity by discharging
Intermediate conductance Ca2+-activated K+
channels are the product of the IKCa1 genes (also known as IK1, hKCa4,
hSK4, KCNN4) and are important in regulating the membrane potential of
colonic epithelial cells, and lymphocytes, and in the volume regulation of red blood cells (16-20). IKCa channels have an
intermediate single channel conductance of 11 picosiemens in
sodium and 40 picosiemens in potassium Ringer, are voltage-independent,
and open in response to changes in intracellular Ca2+. The
protein has six transmembrane segments, internal N and C termini, and
its C terminus is complexed to calmodulin, the channel calcium sensor
(21). The azole antimycotic, clotrimazole
(CLT),1 blocks this channel
with nanomolar affinity, and triarylmethane analogs of CLT are highly
selective and potent inhibitors of the human IKCa1 channel (22).
Scorpion toxin charybdotoxin (ChTX) also blocks hIKCa1, and a selective
analog, ChTx-Glu32, has been generated by structure-guided
design (23). These highly selective reagents provide probes for
analyzing the role of IKCa1 in Ca2+-mediated signaling events.
Because hIKCa1 regulates specific immune responses mediated by T
lymphocytes (20, 24), we tested whether a KCa channel could
participate in innate immune responses to bacteria by modulating calcium signaling during Paneth cell secretion. In this report, mouse
Paneth cells in small intestinal epithelium are shown to express
mIKCa1, and pharmacologic inhibition of IKCa1 with highly selective
triarylmethanes (22) diminished cryptdin secretion in response to
bacteria and lipopolysaccharide (LPS).
Preparation of a Mouse Small Intestinal Crypt cDNA
Library--
Crypts from the small intestines of adult Swiss Webster
mice were prepared using EDTA dissociation (10, 25-27). Fractions consisting of >90% crypts were obtained by agitation of small intestinal segments in nominally Ca2+,
Mg2+-free phosphate-buffered saline with 30 mM
EDTA. Total crypt cellular RNA was isolated (28, 29), from which
poly(A)-containing mRNA was purified by oligo(dT)-cellulose
chromatography. A custom cDNA library was constructed by Stratagene
Cloning Systems, Inc. (La Jolla, CA) using crypt mRNA as template
for reverse transcription of single-stranded cDNA with
oligo(dT)18-20 to prime the reverse transcriptase reaction
from the mRNA 3' termini. Double-stranded cDNAs with adapted
termini were cloned in the EcoRI and XhoI sites of the phagemid vector Uni-ZAP XR (Stratagene Cloning Systems). Cloning
was performed without polymerase chain reaction (PCR) amplification of
sequences or size exclusion of low molecular weight mRNAs. The
library contained ~9.8 × 106 primary clones and was
amplified to a working titer of 3.9 × 1010
plaque-forming units/ml.
Cloning of Mouse Crypt mIKCa1 cDNA--
Bacteriophages
containing mIKCa1 were identified in the crypt library by screening
~5 × 106 plaque-forming units in duplicate by
hybridization at 42 °C in 1 M NaCl, 50% formamide, 10%
dextran sulfate, and 1% SDS with 32P-labeled probes
consisting of 360 bp from the 5'-NCR of hIKCa1 (GenBankTM accession number AF033021).
Filters were washed three times with continuous agitation at 50 °C
with 0.5 × SSC (1 × SSC = 150 mM NaCl, 15 mM sodium citrate), 1% SDS, and autoradiograms were exposed at RT-PCR Detection of mIKCa1 mRNA--
Intact crypts and villi
were prepared as described previously (10). Crypts were bisected
by suspending crypt preparations at low density in 0.6% agarose in PBS
at 50 °C, poured onto the surface of a microscope slide, and allowed
to solidify. Individual crypts were bisected under phase microscopy
using pulled capillary pipettes that were broken to produce knife
edges. For preparation and isolation of single Paneth cells, crypt
preparations were incubated in 2 ml of Hanks' balanced salt
solution with 150 units/ml collagenase (Sigma) at 37 °C for
15 min. Cells were deposited by centrifugation at 1500 rpm for 5 min in
a Beckman GS-6R centrifuge, resuspended, and washed two times with
ice-cold PBS, and the preparation was centrifuged through a 30-µm
filter Cell Strainer cap (Falcon model 352235). Paneth cells and
agranular crypt epithelial cells were identified under phase
microscopy, drawn into capillary tubes and transferred to PCR reaction
tubes for amplification.
For RT-PCR experiments, isolated villi, intact crypts, bisected crypts,
or isolated single Paneth cells were transferred to individual
microcentrifuge tubes, sonicated in 1 µl of RNAguard RNase
inhibitor, and stored at
Detection of mIKCa1 required an additional round of amplification using
the following set of internal amplimers: mIKCa1F2, 5'-ACATG ATCCT GTGCG
ACCTG corresponding to nucleotides 1293-1312 on the mIKCa1 sense
strand and also in exon 7 paired with mIKCa1R2, 5'-TCAAC GTGGA TCCAC
GTGGG corresponding to nucleotides 1567-1586 on the mIKCa1 antisense
strand in exon 8. Samples consisting of 5 µl of 1:100 dilutions of
the initial RT-PCR reaction products were used as template for nested
amplification. PCR mixes lacking AmpliTaq DNA Polymerase were preheated
at 94 °C for 2 min, then complete reaction mixes were cycled as
before. Samples of the PCR reactions were analyzed by separation in 2%
agarose gels to visualize the 293-bp product, and the fragments were
purified with QIAEX II gel extraction kit (Qiagen, Valencia,
CA) or transferred to nylon membranes to identify mIKCa1 by
hybridization with an hIKCa1 probe (29, 30). Amplification of mIKCa1
was performed a minimum of four times on unstained, freshly prepared
crypts. The 293-bp amplification product was cloned into the TOPO II TA cloning vector (Invitrogen), and its identity as the appropriate region
of mIKCa1 sequence was confirmed by DNA sequencing (data not shown).
Inhibition of Paneth Cell Secretion by mIKCa1-specific
Blockers--
To test for a role for mIKCa1 in Paneth cell
secretion, the inhibitory effects of K+ channel blockers
were tested in an ex vivo crypt assay system as described
previously (10, 27). One-thousand crypts were incubated in 1 ml
of isotonic PIPES buffer, consisting of 10 mM PIPES with
0.8% sodium gluconate (pH 7.4), with the appropriate inhibitor plus
106 colony-forming units (cfu) Salmonella
typhimurium, Escherichia coli, or E. coli
LPS (Sigma) or in buffer alone at 37 °C for 30 min. Samples of
elicited secretions were collected and analyzed for bactericidal
activity and in Western blots for cryptdins. Samples (10 µl) of
collected secretions or control supernatants were tested for
bactericidal activity against 1,000 cfu of the defensin-sensitive
S. typhimurium phoP Western Blot Analysis--
Proteins extracted from collected
secretions were analyzed for cryptdins by Western blotting following
separation by acid-urea PAGE. Briefly, the samples were analyzed on a
12.5% acrylamide acid-urea PAGE gel containing 5 M urea as
described previously (10). For Western blot analysis, resolved
Paneth cell protein secretions were transferred from gels to
nitrocellulose membranes (0.22 µm), and blocked membranes were
incubated sequentially with rabbit anti-mouse cryptdin-1 antibody
(1:500), peroxidase-conjugated anti-rabbit IgG (1:10,000), and
chemiluminescent substrate (SuperSignal, Pierce), and x-ray films were
exposed to blots as described previously (10).
Electrophysiology of mIKCa1--
The mIKCa1 coding region was
cloned into pcDNA 3.1, and the construct was transiently
transfected into COS-7 cells with FuGENE 6 (Roche Molecular
Biochemicals) according to the manufacturer's protocol. The
pharmacology of mIKCa1 was determined in the whole cell mode of the
patch-clamp technique using a holding potential of Cloning of mIKCa1 cDNA from Adult Mouse Small Intestinal
Crypts--
A cDNA library prepared from isolated adult mouse
small intestinal crypts was screened in duplicate with a probe from the 5'-NCR of hIKCa1 (GenBankTM accession number
AF033021). Forty-six positive clones with identical or overlapping
restriction patterns were identified in the mouse crypt library. The
complete 1278-bp coding sequence was obtained in several isolates, but
the remaining 175 bp of 5'-NCR was determined by 5'-rapid amplification
of cDNA ends. The composite mIKCa1 sequence contains 302 bp of
5'-NCR, 1278 bp of coding sequence, and 496 bp of 3'-NCR. The sequence
is identical to amplified mIKCa1 coding regions from the MEL murine
erythroleukemia cell line characterized previously (GenBankTM accession
numbers AF042487, AF072884, and NM_008433) and with full-length mIKCa1 cDNA from mouse embryonic liver (GenBankTM accession
number AK010943). mIKCa1 cDNA alignments with existing mouse
genomic DNA sequences (GenBankTM accession numbers AC073693 and
AC073810) showed that the intron-exon organization of the mIKCa1 gene
is identical to that in the hIKCa1 homologue (Fig.
1). Comparison of the hIKCa1 cDNA and
genomic sequences (GenBankTM accession numbers AF022797 and
AF305731-AF305735) with mIKCa1 sequences revealed >90% nucleotide
sequence identity from nucleotide 97 of the human transcript through
the coding region and 3'-NCR. The hIKCa1 coding region is 6 nucleotides
longer than mIKCa1, coding for two additional residues in the S3-S4
loop. The deduced mIKCa1 protein differs from hIKCa1 at 53 additional
positions, most differences being in the S2 and S3 segments, and in the
C terminus. These cloning results show that mIKCa1 is expressed by
mouse small intestinal crypt epithelium.
mIKCa1 mRNA Is Expressed Selectively in Paneth Cells in the
Mouse Small Intestine--
The intestinal epithelial cell lineages
that express the mIKCa1 gene in mouse small intestinal epithelium were
determined using a nested RT-PCR assay. Consistent with previous
reports (18, 20), RT-PCR analysis of whole organ RNA showed that mIKCa1 mRNA was present in adult mouse bone marrow, spleen, liver, kidney, testis, heart, stomach, small intestine, cecum, and colon (data not
shown). Also, mIKCa1 mRNA was amplified equivalently from whole
organ RNA throughout the gastrointestinal tract, and its detection in
neonatal mouse small bowel RNA (not shown) showed that mIKCa1 gene
expression precedes crypt ontogeny and the differentiation of
epithelial cell lineages. Because amplification of whole organ RNA
provides no information as to sites of gene expression, we attempted to
determine the cell types expressing mIKCa1 mRNA in small bowel by
in situ hybridization. However, mIKCa1 mRNA levels were
insufficient to detect hybridization, and therefore small intestinal
mIKCa1 expression was investigated by the RT-PCR analysis of isolated
epithelial structures and cells.
In mice, Paneth cells were the primary small intestinal epithelial cell
lineage found to express mIKCa1. To identify the small intestinal cell
types expressing mIKCa1, nested RT-PCR assays were performed on
isolated intact villus epithelium (Fig.
2A, "arrow a"),
intact crypts (Fig. 2A, "arrow b"), bisected
crypts (Fig. 2A, "arrows c and
d"), single Paneth cells (Fig. 2A,
"arrows g and h"), or single undifferentiated
crypt cells (Fig. 2A, "arrows i and
j"). Individual structures or cells were transferred to separate microfuge tubes, mIKCa1 cDNA was amplified using
sequence-specific nested amplimers, and the products were analyzed by
gel electrophoresis (see "Experimental Procedures"). mIKCa1
mRNA was detected in intact crypts (Fig. 2B, lane
b) but not in villus epithelium (Fig. 2B, lane
a), and analyses of bisected crypts showed that mIKCa1 mRNA was present only in the lower portion of the crypt (Fig. 2B,
lane d) but not in the upper half (Fig. 2B,
lane c). Since the lower half of the crypt contains Paneth
cells as well as undifferentiated crypt epithelial cells that are
agranular, RT-PCR assays were conducted on both these cell populations
isolated from single cell suspensions of isolated crypts (see
"Experimental Procedures"). Although Fig. 2 shows Paneth cells in
crypts stained selectively with Amido Black (see "Experimental
Procedures"), all RT-PCR experiments reported here were performed on
unstained crypts and are representative of four separate
determinations. Single cell RT-PCR detected mIKCa1 mRNA only in
Paneth cells (Fig. 2B, lanes g and h,
respectively, containing one or five individual Paneth cells), but not
in agranular crypt epithelial cells (Fig. 2B, lanes
i and j, one or five cells, respectively).
Glyceraldehyde-3-phosphate dehydrogenase mRNA was amplified using
RNA from all sources in Fig. 2 that were negative for mIKCa1 products
(data not shown). Hybridization of a mIKCa1 cDNA probe to a
Southern blot of the gel shown in the upper panel of Fig.
2B was consistent with identification of the amplification products as mIKCa1 sequences (Fig. 2B, lower
panel). The authenticity of the amplified products was verified by
DNA sequence analysis (data not shown).
mIKCa1 and hIKCa1 Are Pharmacologically
Indistinguishable--
Because mouse and human IKCa1 differ at 55 amino acid residue positions (13% difference), we compared the
properties of the mouse channel heterologously expressed in COS-7 cells
with that of human IKCa1. In the representative inside-out patch shown
in Fig. 3A, mIKCa1 currents
were induced by 1 µM free Ca2+, but not by 50 nM Ca2+, confirming the Ca2+
dependence of this channel. In experiments done in the whole cell mode,
the reversal potential of the mIKCa1 current shifted from mIKCa1 Blockers Suppress Paneth Cell Secretory Responses to
Bacteria and LPS--
The selective expression of mIKCa1 in Paneth
cells of mouse small intestinal epithelium suggested that mIKCa1 may
regulate Ca2+-mediated events in Paneth cell secretion
(15). To test this concept, the effects of mIKCa1 channel blockers were
tested as inhibitors of Paneth cell
In the presence of 1 µM ChTX-Glu32 or CLT,
the quantity of bactericidal activity secreted by Paneth cells in
crypts exposed to S. typhimurium was inhibited by ~50%
compared with crypts not exposed to blockers (Fig.
4A). Further studies with CLT
showed that the inhibition was dose-dependent (Fig.
4B), and similar results were obtained with crypts exposed
to 1000 cfu/crypt E. coli (data not shown). Although these
findings were consistent with the involvement of mIKCa1 in Paneth cell
secretory responses to bacteria, we perceived the need to test
additional inhibitory agents with greater specificities. For example,
ChTX, an agent used in preliminary experiments (Fig. 4C and
data not shown) also blocks the BKCa, Kv1.2, and Kv1.3
channels (31), and CLT inhibits cytochrome P450-dependent
enzymes (32-34) in the concentration range that blocks mIKCa1 (Fig.
3). Therefore, to test for mIKCa1 involvement in Paneth cell secretion
of bactericidal peptide activity more specifically, the inhibitory
effects of more selective mIKCa1 blockers were evaluated. As shown in
Fig. 4, A and C, ChTX-Glu32,
selective for IKCa1 over Kv1.2 and Kv1.3 (23) (Fig. 3), inhibited bacterial and LPS-stimulated secretion of bactericidal peptide activity
to the same extent as ChTX (Fig. 4C). The highly selective IKCa1 blockers TRAM-34 and TRAM-39 also inhibited LPS-triggered Paneth
cell release of bactericidal peptide activity at 200 nM, nearly equivalent to the level of inhibition obtained using 1 µM CLT. On the other hand, the inactive analog TRAM-7 had
no measurable inhibitory effect on secretion (Fig. 4C). None
of the inhibitors was inherently bactericidal, and none stimulated
Paneth cells to release granules (data not shown). These findings
implicate the mIKCa1 channel as a specific modulator of Paneth cell
To evaluate the effects of mIKCa1 blockers on cryptdin secretion,
Paneth cell secretions collected from crypts exposed to bacteria (Fig.
4, A and B) or LPS (Fig. 4C) were
dialyzed, separated by acid-urea PAGE, and probed in Western blots with
anti-cryptdin-1 antibody (Fig. 5). As
reported previously (10), S. typhimurium evoked secretion of
activated cryptdins (Fig. 5, A and B, lanes 1), and no measurable cryptdin was released when crypts were
incubated for 30 min in isotonic buffer without stimuli (Fig.
5A, lane 4; Fig. 5B, lane
5). Consistent with the inhibitory effects of
ChTX-Glu32 and CLT on release of bactericidal peptide
activity (Fig. 4, A and B), 1 µM
ChTX-Glu32 or 1 µM CLT reduced
cryptdin-specific immunoreactivity in Paneth cell secretions elicited
by bacteria (Fig. 5A), and this effect was
dose-dependent (Fig. 5B). CLT (1 µM) and the specific IKCa1 inhibitors TRAM-34 and TRAM-39
(200 nM) also diminished LPS-induced cryptdin release from
Paneth cells (Fig. 5C). These findings and those in Fig. 4
provide evidence that mIKCa1 has a role in Paneth cell secretion in
response to infectious challenge, disclosing potential implications for
innate immunity in small intestinal crypts exposed to bacteria.
From evidence of their secretion of cryptdins in response to
bacteria and bacterial antigens, Paneth cells are inferred to participate in innate immunity in the crypt microenvironment and perhaps above the crypt-villus junction as well (10, 27). The highly
restricted expression of mIKCa1 in Paneth cells of the small bowel, and
the inhibition of bacterial stimulated Paneth cell secretion by highly
selective mIKCa1 blockers, identify mIKCa1 as a functional marker for
Paneth cells. Other intestinal cells may express mIKCa1 at levels below
the detection limits of our assays.
Carbamyl choline-induced Paneth cell secretion is associated with a
biphasic increase in cytosolic [Ca2+], where the first
rise in Ca2+ derives from intracellular stores and the
second is dependent on uptake of exogenous Ca2+ (15). The
involvement of the Ca2+-activated mIKCa1 channel in Paneth
cell secretory responses to bacteria and LPS suggests a role for
cytosolic [Ca2+] in this process as well. By analogy to
events in human lymphocytes during the specific immune response, mIKCa1
channels in the Paneth cell membrane would open as cytosolic
[Ca2+] approaches 300 nM, providing the
counterbalancing cation efflux necessary to sustain Ca2+
entry from the external milieu (20, 24, 35). Blockade of mIKCa1 would
depolarize the membrane and attenuate the calcium signaling response
required to generate a complete Paneth cell secretory response. The
mIKCa1 channel may also influence secretion of antimicrobial peptides
from other mucosa in the airway, gingival crevice, oropharynx, or
urogenital epithelium. The involvement of mIKCa1 in Paneth cell
secretion as shown here does not exclude potential roles for other
subtypes of calcium-activated K+ channels in antimicrobial
peptide secretion by any of these cells.
CLT is being evaluated in human clinical trials for the treatment of
secretory diarrheas due to its ability to block IKCa1 in the colonic
epithelium (36, 37). Our finding that highly selective blockers of the
IKCa1 channel diminish secretion of Paneth cell antimicrobial peptides
in response to bacterial exposure suggests that IKCa1 blockade may have
deleterious effects on innate immune mechanisms in the small intestine.
To our knowledge, Paneth cell dysfunction has not been identified with
human disease. However, in mice genetically defective for the
procryptdin-activating metalloproteinase matrilysin, the lack of
activated intestinal We thank Seth Alper for his generous gift of
the mIKCa1 clone for the electrophysiological experiments and Khoa
Nguyen, Hao Truong, and Chialing Wu for excellent technical assistance.
*
This work was supported by National Institutes of Health
Grants DK44632 (to A. J. O), MH59222 (to K. G. C.), and
NS14609 (to M. D. C.) and by Western States Affiliate of the
American Heart Association Award 9920014Y (to H. W.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed: Dept. of Pathology,
College of Medicine, University of California, D-440, Medical Science
1, Irvine, CA 92697-4800. Tel.: 949-824-4647; Fax: 949-824-1098; E-mail: aouellet@uci.edu.
Published, JBC Papers in Press, November 27, 2001, DOI 10.1074/jbc.M107507200
The abbreviations used are:
CLT, clotrimazole;
ChTX, charybdotoxin;
KCa, calcium-activated K+
channel;
IKCa, intermediate conductance KCa;
LPS, lipopolysaccharide;
NCR, noncoding region;
RT, reverse
transcriptase;
TRAM, triarylmethane;
TRAM-3, (2-chlorophenyl)diphenylmethanol;
TRAM-7, 1-tritylpyrroline;
TRAM-34, 1-[(2-chlorophenyl) diphenylmethyl]-1H-pyrazole;
TRAM-39, 2-(2-chlorophenyl)-2,2-diphenylacetonitrile;
PIPES, 1,4-piperazinediethanesulfonic acid;
cfu, colony-stimulating unit(s).
Modulation of Mouse Paneth Cell
-Defensin Secretion by mIKCa1,
a Ca2+-activated, Intermediate Conductance Potassium
Channel*
,
, and
**
Pathology,
§ Physiology and Biophysics, and
Microbiology and
Molecular Genetics, College of Medicine, University of California,
Irvine, California 92697-4800 and the ¶ INSERM U 410, Faculté de Médecine Xavier Bichat,
75018 Paris, France
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-defensins in response to bacteria and bacterial
antigens (Ayabe, T., Satchell, D. P., Wilson, C. L., Parks,
W. C., Selsted, M. E., and Ouellette, A. J. (2000)
Nat. Immunol. 1, 113-138). We now report that the
Ca2+-activated K+ channel mIKCa1 modulates
mouse Paneth cell secretion. mIKCa1 cDNA clones identified in a
mouse small intestinal crypt library by hybridization to human IKCa1
cDNA probes were isolated, and DNA sequence analysis showed that
they were identical to mIKCa1 cDNAs isolated from erythroid cells
and liver. The genomic organization was found to be conserved between
mouse and human IKCa1 as shown by comparisons of the respective
cDNA and genomic sequences. Reverse transcriptase-PCR experiments
using nested primers amplified mIKCa1 from the lower half of bisected
crypts and from single Paneth cells, but not from the upper half of
bisected crypts, villus epithelium, or undifferentiated crypt
epithelial cells, suggesting a lineage-specific role for mIKCa1 in
mouse small bowel epithelium. The cloned mIKCa1 channel was
calcium-activated and was blocked by ten structurally diverse peptide
and nonpeptide inhibitors with potencies spanning 9 orders of magnitude
and indistinguishable from that of the human homologue. Consistent with
channel blockade, charybdotoxin, clotrimazole, and the highly selective
IKCa1 inhibitors, TRAM-34 and TRAM-39, inhibited (~50%) Paneth cell
secretion stimulated by bacteria or bacterial lipopolysaccharide,
measured both as bactericidal activity and secreted cryptdin protein,
but the inactive analog, TRAM-7, did not block secretion. These results
demonstrate that mIKCa1 is modulator of Paneth cell
-defensin
secretion and disclose an involvement in mucosal defense of the
intestinal epithelium against ingested bacterial pathogens.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-helical molecules to
-sheet peptides constrained by
up to four disulfide connectivities, including the covalently closed
circular
-defensins (2). In mammals, the
-defensins are cationic,
3-4-kDa peptides with a characteristic tridisulfide array, and they
occur in phagocytic leukocyte granules from which they mediate
nonoxidative killing of ingested microbial cells following
phagolysosomal fusion (3-5). Varied epithelia also express
- and
-defensins, secreting them onto mucosal surfaces by apparent
constitutive pathways or as secretory granule components of exocytotic
cells (6-13). In crypts of the small intestinal epithelium, Paneth
cells accumulate high levels of
-defensins that are termed cryptdins
in mice, and which they secrete in response to bacterial or
pharmacologic stimuli.
-defensins at millimolar concentrations. Bacteria or bacterial antigens stimulate mouse Paneth cells to release apical secretory granules that contain several bactericidal peptides and proteins of
which the cryptdins account for ~70% of the secreted microbicidal peptide activity (10). The secretory responses occur within minutes of
exposure to soluble bacterial antigens or to carbamyl choline
and are dose-dependent, suggesting a receptor-mediated process (10). In mouse small intestinal crypts stimulated with carbamyl
choline, the cytosolic calcium dynamics change only in Paneth cells in
a biphasic pattern consistent with mobilization of intracellular
Ca2+ stores followed by influx of extracellular
Ca2+ (14, 15). These observations led to the hypothesis
that Paneth cell secretion in response to bacterial stimuli may be
modulated by a cation-selective channel that could regulate the influx
of extracellular Ca2+.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
70 °C. Forty-six positive clones were identified, shown
to have identical or overlapping restriction patterns, and all clones
sequenced within the IKCa1 coding region were identical to mIKCa1.
Plaque-purified phage were excised to plasmid forms and subjected to
digestion with restriction enzymes and DNA sequence analysis. All
clones corresponded to the mouse Ca2+-activated
K+ channel, mIKCa1. The complete mouse intestinal
mIKCa1 sequence was determined by cloning the remaining
5'-flanking by 5'-rapid amplification of cDNA ends using
oligonucleotide primers mCK1m1, 5'-ATGGC CCCTG AGGTC TTGGG GCTCA GCCAG
CTT (nucleotides 145-177 on the mIKCa1 antisense strand); mCK1m2,
5'-TGCCC AGGGT CCCCC ACCTC TCAGT ACTGC AAAT (nucleotides 109-142 on
the mIKCa1 antisense strand), and mCK1mR, 5'-TTCTC CTGCT CCAGC AGGCG
CTTTC TCCGT CTCA (nucleotides 210-243 on the mIKCa1 antisense strand)
as primers in the 5'-rapid amplification of cDNA ends System
Version 2.0 (Invitrogen). The complete mouse intestinal crypt
mIKCa1 cDNA sequence was identical to those reported previously
from mouse bone marrow (GenBankTM accession numbers
AF042487 and NM008433) and embryonic mouse liver (GenBankTM
accession number AK010943).
70 °C. Detection of mIKCa1 required that
RT-PCR be performed with nested primer sets. RNA from intestinal epithelial cells and structures were amplified with GeneAmp EZ rTth RNA PCR kit (PerkinElmer Life Sciences). Samples (500 ng) of total RNA from mouse bone marrow, spleen, liver, kidney, testis, heart, stomach, small intestine (proximal, mid, distal), cecum, colon,
and developing small intestine also were analyzed similarly (data not
shown). The external amplimers consisted of primers mIKCa1F1, 5'-GCCAG
GTACG GCTGA AACAC, which corresponds to nucleotides 1224-1244 on the
mIKCa1 sense strand within exon 7 and mIKCa1R1, 5'-CGTGG GAGGT CCAAT
TCAGT, which corresponds to nucleotides 1624-1643 on the mIKCa1
antisense strand in exon 8. Reaction mixes were denatured and subjected
to 45 cycles as follows: 94 °C, 1 min; 50 °C, 1.5 min; 72 °C,
2 min with a final extension reaction of 9 min at 72 °C terminated
by rapid cooling to 4 °C.
strain in 40 µl of PIPES buffer, and
surviving bacteria were quantitated as cfu on nutrient agar after
overnight growth at 37 °C (10). In this assay, ~1000 crypts were
suspended in 1 ml of a nominally calcium-free medium (10 mM
PIPES, 0.8% sodium gluconate (pH 7.4)) and exposed to 1 × 106 bacterial cfu per crypt or to 100 ng/ml E. coli LPS to elicit Paneth cell secretion (10). All experiments
were repeated a minumum of three times on freshly prepared crypts.
80 mV. A pipette
solution containing 145 mM K+ aspartate, 10 mM K2EGTA, 8.5 mM
CaCl2, 2.0 mM MgCl2, and 10 mM HEPES (pH 7.2, 290-310 mosM), with a
calculated free [Ca2+]i of 1 µM was
used to activate mIKCa1. To eliminate native COS cell chloride
currents, sodium aspartate Ringer solution (160 mM
Na+ aspartate, 4.5 mM KCl, 2 mM
CaCl2, 1 mM MgCl2, 5 mM
HEPES (pH 7.4), 290-310 mosM) was used as an
external solution. Currents were elicited by 200-ms voltage ramps from
120 to 40 mV every 10 s, and the reduction of slope conductance
at
80 mV by channel antagonists were taken as a measure of channel
blocking. The recording in Fig. 3A was done on excised
inside-out patches with the external solution described above as
pipette solution. K+ aspartate solutions containing 1 µM and 50 nM free [Ca2+] were
applied to the cytoplasmic side of the patch. CLT, econazole, and
tetraethylammonium were from Sigma; nifedipine was from RBI (Natick, MA); ChTX, ChTX-Glu32, and ShK
(Stichodactyla helianthus toxin) were from Bachem
Biosciences (King of Prussia, PA). The synthesis and specificities of
ChTX-Glu32 (23) and the triarylmethanes TRAM-3, TRAM-7,
TRAM-34, and TRAM-39 have been described previously
(22).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (37K):
[in a new window]
Fig. 1.
Comparison of genomic organization and
intron-exon junctions of mouse and human IKCa1. The putative
transmembrane segments (S1-S6) in the coding region, the 5'- and
3'-NCR, and the intron-exon junctions (arrowheads) are
depicted in the schematic at the top of the figure.
Donor and acceptor splice site sequences at each of the conserved
exon-intron boundaries between mIKCa1 and hIKCa1 are shown below.
Consensus GT-AG (5'-3') splice site sequences are observed at each
junction.

View larger version (49K):
[in a new window]
Fig. 2.
mIKCa1 mRNA in mouse Paneth cells.
Crypts, villi, and crypt cell preparations are described under
"Experimental Procedures." A, individual isolated villi
(arrow a), intact crypts (arrow b),
crypts bisected as shown (arrows c and d), single
Paneth cells (arrows g and h), and agranular
crypt epithelial cells (arrows i and j) are shown
under phase microscopy. In the center and lower panels, epithelia and
cells are shown after staining 2 min with 0.05% Amido Black, a
selective Paneth cell stain under these conditions, but all RT-PCR
amplifications were performed on unstained preparations. mIKCa1
sequences in individual, unstained isolated villi (arrow a),
intact crypts (arrow b), upper (arrow c) and
lower (arrow d) portions of bisected crypts, one or five
isolated Paneth cells (arrows g and h,
respectively), or one or five isolated agranular crypt epithelial cells
(arrows i and j) are shown. B, lanes
labeled a-d and g-j correspond to samples of
nested mIKCa1 products amplified from cells and structures as denoted
in A. Lane e contains mIKCa1 products amplified
from 500 ng of total adult mouse small bowel RNA; and lane f
contains a sample from an identical reaction to which no template RNA
had been added. The lower half of B shows an autoradiogram
of a Southern blot of the gel in the upper half after hybridization
with an mIKCa1 cDNA probe. Arrows denote the position of
the mIKCa1-specific product.
80 mV in
sodium Ringer solution to 0 mV in potassium Ringer, consistent with the
channel being potassium-selective (Fig. 3B). We also
conducted a detailed pharmacological analysis of mIKCa1 using a panel
of ten inhibitors that are known to block hIKCa1 in a potency range
spanning 9 log units (20, 21). Representative traces for four compounds
(TRAM-34, ChTX-Glu32, CLT, and TRAM-7) are shown in Fig. 3,
C-F, and dose-response curves for all ten compounds are
shown in detail in Fig. 3G. The Kd-values
(mean + S.D.) obtained for the mouse channel are identical to those
reported for the human homologue, hIKCa1 (20, 21). Earlier published
data demonstrated that the single channel conductances of mIKCa1 and
hIKCa1 are identical (17, 18). Taken together, these findings show that
the biophysical and pharmacological properties of the mIKCa1 channel
are indistinguishable from those of hIKCa1, allowing the previously
characterized and selective inhibitors of hIKCa1, TRAM-34, TRAM-39, and
ChTX-Glu32 to be applied to functional studies of mIKCa1 in
Paneth cells.

View larger version (27K):
[in a new window]
Fig. 3.
Electrophysiological properties of mIKCa1
expressed in COS-7 cells. A, representative IK
conductance in a single excised inside-out patch in the presence of 1 µM and 50 nM free [Ca2+],
demonstrating the calcium dependence of the current. This experiment
was repeated on five additional patches. B, representative
IK current recorded in the whole-cell mode in a COS-7 cell transfected
with mIKCa1. In this experiment, the bath solution was changed from 160 mM sodium aspartate to 160 mM potassium, and
the shift in reversal potential from
80 mV to 0 mV demonstrated the
potassium selectivity of the current. This experiment was repeated on
10 additional cells. C-F, inhibitory effects of 25 nM TRAM-34, 100 nM
ChTX-Glu32, 100 nM CLT, and 10 µM
TRAM-7 on representative whole-cell IK currents. G,
pharmacology of mIKCa1. Kd values were determined by
testing every compound three times at four concentrations and fitting
the Hill equation (nH) to the reduction of slope
conductance at
80 mV. Mean + S.D. are shown.
, ChTX
(Kd = 4 ± 1 nM,
nH = 1.05);
, TRAM-34 (Kd = 21 ± 3 nM, nH = 1.18);
,
ShK (Kd = 26 ± 3 nM,
nH = 1.08);
, ChTX-Glu32
(Kd = 37 ± 4 nM,
nH = 0.97);
, TRAM-39 (Kd = 75 ± 10 nM, nH = 1.14);
,
CLT (Kd = 80 ± 9 nM,
nH = 1.12);
, TRAM-3 (Kd = 490 ± 30 nM, nH = 1.05);
,
nifedipine (Kd = 4.2 ± 0.4 µM,
nH = 1.08);
, econazole
(Kd = 11 ± 0.9 µM,
nH = 1.1);
, TRAM-7 (Kd > 25 µM);
, tetraethylammonium (Kd = 28 ± 3 mM, nH = 1.03).
-defensin secretion following
exposure to S. typhimurium or E. coli or to 100 ng/ml LPS for 30 min (10). Because cryptdins localize exclusively to
Paneth cell secretory granules in the small intestine and account for
70% of the bactericidal activity in Paneth cell secretions (10),
bactericidal peptide activity assays provide a sensitive and accurate
index of Paneth cell secretion. Accordingly, the effects of IKCa1
blockers on secretory activity were evaluated by measuring
antimicrobial peptide activity in elicited secretions, and cryptdin
secretion was confirmed biochemically by Western blot analyses.
-defensin release in response to bacteria or LPS.

View larger version (22K):
[in a new window]
Fig. 4.
Effects of mIKCa1 inhibition on Paneth cell
secretion of bactericidal peptide activity. A,
secretions were collected from crypts (~1000) resuspended in isotonic
sodium gluconate buffer containing 1 µM CLT or 1 µM ChTX-Glu32 coincubated with S. typhimurium at 37 °C for 30 min. Stimulated secretions or
control supernatants were collected, and the bactericidal activity of
10-µl samples were tested against ~500 cfu of defensin-sensitive
S. typhimurium (10). Surviving bacteria were quantitated as
colony-forming units following overnight growth. Data points represent
individual triplicate determinations in two separate experiments. For
each series of data points, plus characters denote presence
of S. typhimurium with crypts as bacterial secretory
stimuli, and minus signs denote crypts incubated in the
absence of bacteria as negative controls for secretion. Similarly, CLT
or ChTX-Glu32 blocking agents were present as noted, and
minus signs denote crypts incubated in the absence of either
blocker. B, secretions were collected from crypts stimulated
with S. typhimurium in the presence of increasing
concentrations of CLT, and the bactericidal activity of 10-µl samples
of secretions was assayed as described in A and expressed as
mean percent inhibition of bacterial cell killing ± S.D.
(n = 3), relative to secretions stimulated by S. typhimurium in the absence of blocking agent. C,
secretions were collected from crypts stimulated with 100 ng/ml LPS in
the presence or absence of 200 nM TRAM-34, TRAM-39, or
TRAM-7 or 1 µM CLT, ChTX, or ChTX-Glu32 as in
B. The bactericidal activity of 10-µl samples was measured
and expressed as described in B, relative to secretions
released by stimulation with LPS in the absence of IKCa1
inhibitors.

View larger version (51K):
[in a new window]
Fig. 5.
Inhibition of cryptdin secretion by selective
inhibitors of IKCa1. Proteins were extracted from secretions
collected from crypts incubated with bacteria in the presence or
absence of CLT or ChTX-Glu32 (Fig. 4A),
increasing dosages of CLT (Fig. 4B), or with 100 ng/ml LPS
in the presence of 200 µM TRAM-34, TRAM-39, or 1 µM CLT (Fig. 4C). Cryptdins were detected by
Western blot analysis following acid-urea PAGE (see "Experimental
Procedures" (10), and arrows indicate immunoreactive
cryptdins in all panels. Lanes: plus characters
denote presence of bacterial or LPS secretory stimuli as noted, and
minus characters denote absence of a bacterial or
LPS secretory stimulus. Similarly, plus and minus
characters denote the respective presence or absence of
blockers as noted. Crp1 denotes lanes containing 1 µg of
synthetic cryptdin-1.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-defensins correlates with a diminished ability
of the mice to clear orally administered enteric infections, and
matrilysin-null mice are 10-fold more susceptible to systemic disease
caused by S. typhimurium infection (27). Defects in mIKCa1
expression or function could adversely affect enteric host defense by
attenuating secretory responses to infection and perhaps increasing
host susceptibility to bacterial colonization.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Cociancich, S.,
Dupont, A.,
Hegy, G.,
Lanot, R.,
Holder, F.,
Hetru, C.,
Hoffmann, J. A.,
and Bulet, P.
(1994)
Biochem. J.
300,
567-575
2.
Borregaard, N.,
Elsbach, P.,
Ganz, T.,
Garred, P.,
and Svejgaard, A.
(2000)
Immunol. Today
21,
68-70[CrossRef][Medline]
[Order article via Infotrieve]
3.
Ganz, T.,
and Lehrer, R. I.
(1997)
Curr. Opin. Hematol.
4,
53-58[Medline]
[Order article via Infotrieve]
4.
Ganz, T.,
Selsted, M. E.,
Szklarek, D.,
Harwig, S. S.,
Daher, K.,
Bainton, D. F.,
and Lehrer, R. I.
(1985)
J. Clin. Invest.
76,
1427-1435
5.
Martin, E.,
Ganz, T.,
and Lehrer, R. I.
(1995)
J. Leukoc. Biol.
58,
128-136[Abstract]
6.
Schonwetter, B. S.,
Stolzenberg, E. D.,
and Zasloff, M. A.
(1995)
Science
267,
1645-1648 7.
Goldman, M. J.,
Anderson, G. M.,
Stolzenberg, E. D.,
Kari, U. P.,
Zasloff, M.,
and Wilson, J. M.
(1997)
Cell
88,
553-560[CrossRef][Medline]
[Order article via Infotrieve]
8.
Quayle, A. J.,
Porter, E. M.,
Nussbaum, A. A.,
Wang, Y. M.,
Brabec, C.,
Yip, K. P.,
and Mok, S. C.
(1998)
Am. J. Pathol.
152,
1247-1258[Abstract]
9.
Valore, E. V.,
Park, C. H.,
Quayle, A. J.,
Wiles, K. R.,
McCray, P. B., Jr.,
and Ganz, T.
(1998)
J. Clin. Invest.
101,
1633-1642[Medline]
[Order article via Infotrieve]
10.
Ayabe, T.,
Satchell, D. P.,
Wilson, C. L.,
Parks, W. C.,
Selsted, M. E.,
and Ouellette, A. J.
(2000)
Nat. Immunol.
1,
113-138[CrossRef][Medline]
[Order article via Infotrieve]
11.
Bals, R.,
Goldman, M. J.,
and Wilson, J. M.
(1998)
Infect. Immun.
66,
1225-1232 12.
Bals, R.,
Wang, X., Wu, Z.,
Freeman, T.,
Bafna, V.,
Zasloff, M.,
and Wilson, J. M.
(1998)
J. Clin. Invest.
102,
874-880[Medline]
[Order article via Infotrieve]
13.
Diamond, G.,
and Bevins, C. L.
(1998)
Clin. Immunol. Immunopathol.
88,
221-225[CrossRef][Medline]
[Order article via Infotrieve]
14.
Satoh, Y.,
Ishikawa, K.,
Oomori, Y.,
Takeda, S.,
and Ono, K.
(1992)
Cell Tissue Res.
269,
213-220[CrossRef][Medline]
[Order article via Infotrieve]
15.
Satoh, Y.,
Habara, Y.,
Ono, K.,
and Kanno, T.
(1995)
Gastroenterology
108,
1345-1356[CrossRef][Medline]
[Order article via Infotrieve]
16.
Ishii, T. M.,
Silvia, C.,
Hirschberg, B.,
Bond, C. T.,
Adelman, J. P.,
and Maylie, J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11651-11656 17.
Logsdon, N. J.,
Kang, J.,
Togo, J. A.,
Christian, E. P.,
and Aiyar, J.
(1997)
J. Biol. Chem.
272,
32723-32726 18.
Vandorpe, D. H.,
Shmukler, B. E.,
Jiang, L.,
Lim, B.,
Maylie, J.,
Adelman, J. P.,
de Franceschi, L.,
Cappellini, M. D.,
Brugnara, C.,
and Alper, S. L.
(1998)
J. Biol. Chem.
273,
21542-21553 19.
Joiner, W. J.,
Wang, L. Y.,
Tang, M. D.,
and Kaczmarek, L. K.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11013-11018 20.
Ghanshani, S.,
Wulff, H.,
Miller, M. J.,
Rohm, H.,
Neben, A.,
Gutman, G. A.,
and Cahalan.
(2000)
J. Biol. Chem.
275,
37137-37149 21.
Fanger, C. M.,
Ghanshani, S.,
Logsdon, N. J.,
Rauer, H.,
Kalman, K.,
Zhou, J.,
Beckingham, K.,
Chandy, K. G.,
Cahalan, M. D.,
and Aiyar, J.
(1999)
J. Biol. Chem.
274,
5746-5754 22.
Wulff, H.,
Miller, M. J.,
Haensel, W.,
Grissmer, S.,
Cahalan, M. D.,
and Chandy, K. G.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
8151-8156 23.
Rauer, H.,
Lanigan, M. D.,
Pennington, M. W.,
Aiyar, J.,
Ghanshani, S.,
Cahalan, M. D.,
Norton, R. S.,
and Chandy, K. G.
(2000)
J. Biol. Chem.
275,
1201-1208 24.
Fanger, C. M.,
Rauer, H.,
Neben, A. L.,
Miller, M. J.,
Rauer, H.,
Wulff, H.,
Rosa, J. C.,
Ganellin, C. R.,
Chandy, K. G.,
and Cahalan, M. D.
(2001)
J. Biol. Chem.
276,
12249-12256 25.
Bjerknes, M.,
and Cheng, H.
(1981)
Anat. Rec.
199,
565-574[CrossRef][Medline]
[Order article via Infotrieve]
26.
Cano-Gauci, D. F.,
Lualdi, J. C.,
Ouellette, A. J.,
Brady, G.,
Iscove, N. N.,
and Buick, R. N.
(1993)
Exp. Cell Res.
208,
344-349[CrossRef][Medline]
[Order article via Infotrieve]
27.
Wilson, C. L.,
Ouellette, A. J.,
Satchell, D. P.,
Ayabe, T.,
López-Boado, Y. S.,
Stratman, J. L.,
Hultgren, S. J.,
Matrisian, L. M.,
and Parks, W. C.
(1999)
Science
286,
113-117 28.
Darmoul, D.,
and Ouellette, A. J.
(1996)
Am. J. Physiol.
271,
G68-G74 29.
Darmoul, D.,
Brown, D.,
Selsted, M. E.,
and Ouellette, A. J.
(1997)
Am. J. Physiol.
272,
G197-G206 30.
Ghanshani, S.,
Coleman, M.,
Gustavsson, P., Wu, A. C.,
Gargus, J. J.,
Gutman, G. A.,
Dahl, N.,
Mohrenweiser, H.,
and Chandy, K. G.
(1998)
Genomics
51,
160-161[CrossRef][Medline]
[Order article via Infotrieve]
31.
Rauer, H.,
Pennington, M.,
Cahalan, M.,
and Chandy, K. G.
(1999)
J. Biol. Chem.
274,
21885-21892 32.
Ayub, M.,
and Levell, M. J.
(1990)
Biochem. Pharmacol.
40,
1569-1575[CrossRef][Medline]
[Order article via Infotrieve]
33.
Maurice, M.,
Pichard, L.,
Daujat, M.,
Fabre, I.,
Joyeux, H.,
Domergue, J.,
and Maurel, P.
(1992)
FASEB J.
6,
752-758[Abstract]
34.
Fowler, S. M.,
Riley, R. J.,
Pritchard, M. P.,
Sutcliffe, M. J.,
Friedberg, T.,
and Wolf, R. C.
(2000)
Biochemistry
39,
4406-4414[CrossRef][Medline]
[Order article via Infotrieve]
35.
Cahalan, M. D.,
and Chandy, K. G.
(1997)
Curr. Opin. Biotechnol.
8,
749-756[CrossRef][Medline]
[Order article via Infotrieve]
36.
Rufo, P. A.,
Jiang, L.,
Moe, S. J.,
Brugnara, C.,
Alper, S. L.,
and Lencer, W. I.
(1996)
J. Clin. Invest.
98,
2066-2075[Medline]
[Order article via Infotrieve]
37.
Rufo, P. A.,
Merlin, D.,
Riegler, M.,
Ferguson-Maltzman, M. H.,
Dickinson, B. L.,
Brugnara, C.,
Alper, S. L.,
and Lencer, W. I.
(1997)
J. Clin. Invest.
100,
3111-3120[Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
L A Simms, J D Doecke, M D Walsh, N Huang, E V Fowler, and G L Radford-Smith Reduced {alpha}-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease Gut, July 1, 2008; 57(7): 903 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Halm, T. Liao, and D. R. Halm Distinct K+ conductive pathways are required for Cl- and K+ secretion across distal colonic epithelium Am J Physiol Cell Physiol, October 1, 2006; 291(4): C636 - C648. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Hamilton and M. Kiessling DCEBIO stimulates Cl- secretion in the mouse jejunum Am J Physiol Cell Physiol, January 1, 2006; 290(1): C152 - C164. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Bevins Events at the Host-Microbial Interface of the Gastrointestinal Tract V. Paneth cell {alpha}-defensins in intestinal host defense Am J Physiol Gastrointest Liver Physiol, August 1, 2005; 289(2): G173 - G176. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tanabe, T. Ayabe, B. Bainbridge, T. Guina, R. K. Ernst, R. P. Darveau, S. I. Miller, and A. J. Ouellette Mouse Paneth Cell Secretory Responses to Cell Surface Glycolipids of Virulent and Attenuated Pathogenic Bacteria Infect. Immun., April 1, 2005; 73(4): 2312 - 2320. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||